STOCK TITAN
  1. Home
  2. News
  3. HSDT

Helius Medical Technologies Inc - HSDT STOCK NEWS

Welcome to our dedicated news page for Helius Medical Technologies (Ticker: HSDT), a resource for investors and traders seeking the latest updates and insights on Helius Medical Technologies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Helius Medical Technologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Helius Medical Technologies's position in the market.

News
Helius Medical Technologies, Inc. Compliant with All Applicable Nasdaq Listing Criteria
Rhea-AI Summary
Helius Medical Technologies, Inc. receives notice of compliance with Nasdaq bid price requirement
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
35.5%
Tags
none
-
News
Helius Medical Technologies Announces Reverse Stock Split
Rhea-AI Summary
Helius Medical Technologies, Inc. announces 1-for-50 reverse stock split, reducing outstanding shares from 28.30 million to 0.57 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.13%
Tags
none
-
News
Helius Medical Technologies, Inc. Reports Second Quarter 2023 Financial Results
Rhea-AI Summary
HSDT: Helius Medical Technologies, Inc. reports a 115% increase in Q2 2023 revenue compared to Q2 2022, with total revenue of $256 thousand. The company also achieved a 131% increase over Q1 2023. Operating cash burn decreased by $0.9 million compared to Q2 2022. The expansion of the stroke trial at MUSC and the addition of Montefiore Medical Center to the PoNSTEP program are significant developments. The PoNS device has been awarded DMEPOS accreditation, an important step towards reimbursement by CMS. The PTAP concluded on June 30, 2023, and the company has established an ATM offering program to access additional cash. The company aims to secure CMS and third-party payer reimbursement going forward.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.53%
Tags
earnings
News
Helius Medical Technologies, Inc. Announces Participation of Montefiore Medical Center in its PoNS® Therapeutic Experience Program
Rhea-AI Summary
Helius Medical adds Montefiore Medical Center to its PoNS Therapeutic Experience Program for MS patients. Dr. Langston, a renowned researcher, joins the study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.24%
Tags
none
-
News
Helius Medical Technologies, Inc. to Release Second Quarter 2023 Financial Results on August 10, 2023
Rhea-AI Summary
Helius Medical Technologies, Inc. will release its second quarter 2023 financial results on August 10, 2023. The conference call will provide an update on the progress and plans surrounding the U.S. commercialization of PoNS®.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.53%
Tags
earnings
-
News
Helius Medical Technologies, Inc. Expands Stroke Trial at the Medical University of South Carolina
Rhea-AI Summary
Helius Medical Technologies is expanding its trial in stroke patients from 12 to 60 participants. The trial will evaluate the effects of cranial-nerve non-invasive neuromodulation using PoNS Therapy on gait and dynamic balance in chronic stroke survivors. The company aims to leverage the breakthrough designation granted in August 2021 and pursue approval for stroke treatment in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
none
News
Helius Medical Technologies Announces DMEPOS Accreditation for PoNS
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.96%
Tags
none
-
News
Helius Medical Technologies to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.39%
Tags
conferences
-
News
Helius Medical Technologies to Present at LD Micro Invitational XIII 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.56%
Tags
conferences
News
Helius to Highlight Innovative PoNS Therapy™ at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting, in Commemoration of World MS Day
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.5%
Tags
none
Stock HSDT logo
Helius Medical Technologies Inc

Nasdaq:HSDT

HSDT Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

HSDT Stock Data

5.47M
829.47k
0.85%
11.59%
8.14%
Electromedical and Electrotherapeutic Apparatus Manufacturing
Manufacturing
Link
US
Newtown

About HSDT

helius medical technologies, inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. the company's product is portable neuromodulation stimulator (pons), a medical device in canada for the treatment of chronic balance deficit due to mild-to-moderate traumatic brain injury. its pons device treats neurostimulation of cranial nerves via the tongue to restore lost function. the company is headquartered in newtown, pennsylvania.